Table 7: Expected healthcare costs (at 2010/2011 prices) over 2 years following first-line treatment with doxorubicin/ifosfamide combination and trabectedin monotherapy.

ResourceExpected healthcare costs per patient (Euros at 2010/2011 prices) over 2 years following first-line treatment
ItalySpainSweden
Doxorubicin/ifosfamideTrabectedinDoxorubicin/ifosfamideTrabectedinDoxorubicin/ifosfamideTrabectedin

Diagnosis€634.4(2%)€634.4(2%)€1886.5(6%)€1886.5(6%)€2416.8(7%)€2416.8(6%)
First-line cytotoxics€2302.9(6%)€26885.4(66%)€1491.8(5%)€18432.1(54%)€3172.2(9%)€17934.5(45%)
Second-line cytotoxics€17007.3(44%)€2556.9(6%)€6524.1(21%)€1761.6(5%)€8469.5(23%)€3224.8(8%)
Evaluations of response€2025.7(5%)€1641.7(4%)€1280.4(4%)€1098.7(3%)€2758.0(8%)€2453.2(6%)
Hospitalisations for chemotherapy infusion€5093.0(13%)€3765.6(9%)€4704.7(15%)€3564.3(10%)€4326.8(12%)€3685.2(9%)
Outpatient attendances for chemotherapy€291.3(<1%)€338.0(1%)€560.9(2%)€423.4(1%)€998.6(3%)€439.0(1%)
Tests before each cycle of chemotherapy€212.5(<1%)€118.0(<1%)€266.2(1%)€197.9(1%)€244.3(1%)€217.0(1%)
Pre- and postchemotherapy medication€5706.9(15%)€1107.3(3%)€7621.1(25%)€1665.8(5%)€11732.4(32%)€7458.6(19%)
Palliative care€2918.9(8%)€1773.3(4%)€1942.7(6%)€1932.3(6%)€1200.9(3%)€1265.9(3%)
Management of haematological toxicity€2728.6(7%)€1811.1(4%)€4421.0(14%)€3233.7(9%)€1187.2(3%)€685.2(2%)

Total€38921.7(100%)€40631.7(100%)€30699.4(100%)€34196.3(100%)€36506.7(100%)€39780.2(100%)

(Percentage of total expected cost is in parenthesis).